A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea ...

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...

Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

The median BMI of the cohort was 26.7 kg/m 2 (range, 17.9–55.2). Patients were classified into 3 main weight categories based ...

Selinexor-based regimens enhance T-cell activation in RRMM patients, without increasing inhibitory checkpoint molecules, indicating resistance is not due to T-cell exhaustion. Baseline protein ...

The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

Topline results from the phase 3 HERIZON-GEA-01 trial show that the HER2-targeted bispecific antibody zanidatamab-hrii ...

Visugromab combined with nivolumab showed a median duration of response exceeding two years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...